Shopping Cart (0)
My Account

 Shopping Cart
Conferences | Training Courses | Market Reports | Managed Events | Past Conferences | Update Me
SELECTBIO Conferences Circulating Biomarkers World Congress 2016
Conferences  \  Circulating Biomarkers World Congress 2016  \  Agenda  \  Shannon Stott
RegisterLogin

Shannon Stott's Biography


Shannon Stott, Assistant Professor, Massachusetts General Hospital & Harvard Medical School

The Stott laboratory is comprised of bioengineers and chemists focused on translating technological advances to relevant applications in clinical medicine. Specifically, we are interested in using microfluidics and imaging technologies to create tools that increase understanding of cancer biology and of the metastatic process. In collaboration with the Toner, Haber and Maheswaran laboratories, we have developed a microfluidic device that can isolate extraordinary rare circulating tumor cells (CTCs) from the blood of cancer patients. We are striving to employ new imaging modalities to extract as much information as possible from these rare cells while pushing the technology further for early cancer detection. Ultimately, we hope that by working in close partnership with the molecular and cell biologist at the Mass General Cancer Center, we can create new tools that directly impact patient care.

Shannon Stott Image

Microfluidic Liquid Biopsy: Isolation of Exosomes and Circulating Tumor Cells from Cancer Patients

Tuesday, 22 March 2016 at 12:00

Add to Calendar ▼SELECTBIOenquiries@selectbiosciences.com

Aggressive tumors will invade surrounding tissue due to rapidly dividing cancer cells that are nourished by an ample blood supply. As these cancer cells are multiplying, they release thousands of tiny particles into the blood stream, referred to as exosomes, which contain genetic information about the tumor. Whole cancer cells are also released from the tumor and these rare circulating tumor cells (CTCs) provide genetic and functional information about the patient’s cancer. Through a collaborative effort between bioengineers, biologists, and clinicians, our group at MGH has developed microfluidic devices to isolate both of these rare circulating biomarkers from whole blood. Data from these devices will be presented with a focus on our recent effort to characterize exosomes and CTCs from patients with glioblastoma. Through the microfluidic isolation of blood based biomarkers from glioblastoma patients, our goal is to obtain complementary data to the current standard of care radiologic measurements to help better guide treatment for this deadly cancer.

Add to Calendar ▼2016-03-21 00:00:002016-03-22 00:00:00Europe/LondonCirculating Biomarkers World Congress 2016Circulating Biomarkers World Congress 2016 in Boston, USABoston, USASELECTBIOenquiries@selectbiosciences.com


Corporate Sponsors